|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1230218755 |
| 003 |
OCoLC |
| 005 |
20231120010526.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
210111s2021 ne a o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d GZM
|d OPELS
|d OCLCO
|d OCLCF
|d ABC
|d UKMGB
|d UKAHL
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|
| 015 |
|
|
|a GBC0I0443
|2 bnb
|
| 016 |
7 |
|
|a 020013526
|2 Uk
|
| 019 |
|
|
|a 1233321421
|a 1235967879
|
| 020 |
|
|
|a 9780128205372
|q (electronic bk.)
|
| 020 |
|
|
|a 0128205377
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128205365
|
| 020 |
|
|
|z 0128205369
|
| 035 |
|
|
|a (OCoLC)1230218755
|z (OCoLC)1233321421
|z (OCoLC)1235967879
|
| 050 |
|
4 |
|a RC685.C6
|
| 082 |
0 |
4 |
|a 616.1/2306
|2 23
|
| 245 |
0 |
0 |
|a Dual antiplatelet therapy for coronary and peripheral arterial disease /
|c edited by Sorin Brener.
|
| 264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource :
|b illustrations (colour)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a <Ol> <li>Platelets and arterial disease -- initiation, progression and destabilization of atherosclerotic vascular disease</li> <p> <li>Platelet physiology and pharmacology -- relevant considerations for patient care</li> <p> <li>The development of dual antiplatelet therapy -- physiologic and clinical implications of multiple pathway inhibition of platelet function</li> <p> <li>Acute coronary syndromes and percutaneous coronary intervention -- current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data?</li> <p> <li>Peripheral arterial disease -- a different kind of arterial disease? The role of antiplatelet therapy in prevention and treatment of limb ischemia</li> <p> <li>Cerebrovascular disease -- what is the role of DAPT for prevention and treatment of ischemic stroke?</li> <p> <li>Competing risks in DAPT duration of therapy -- the case for shorter treatment</li> <p> <li>DAPT may prevent coronary ischemic events beyond one year -- the case for extended DAPT treatment</li> <p> <li>How to integrate risk of bleeding and ischemic events in clinical medicine? The role of risk scores </li> <p> <li>Moving from DAPT to monotherapy based on P2Y12 receptor blockade -- why it could be a novel paradigm?</li> <p> <li>The conundrum of simultaneous antiplatelet and antithrombotic therapy -- how to resolve it?</li> <p> <li>A look to the future </li> </ol>
|
| 650 |
|
0 |
|a Coronary heart disease
|x Treatment.
|
| 650 |
|
0 |
|a Peripheral vascular diseases
|x Treatment.
|
| 650 |
|
0 |
|a Blood platelets.
|
| 650 |
|
2 |
|a Blood Platelets
|0 (DNLM)D001792
|
| 650 |
|
6 |
|a Maladies vasculaires p�eriph�eriques
|0 (CaQQLa)201-0068268
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
6 |
|a Sang
|x Plaquettes.
|0 (CaQQLa)201-0016716
|
| 650 |
|
7 |
|a Blood platelets.
|2 fast
|0 (OCoLC)fst00834782
|
| 650 |
|
7 |
|a Coronary heart disease
|x Treatment.
|2 fast
|0 (OCoLC)fst00879569
|
| 650 |
|
7 |
|a Peripheral vascular diseases
|x Treatment.
|2 fast
|0 (OCoLC)fst01058169
|
| 700 |
1 |
|
|a Brener, Sorin,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Dual antiplatelet therapy for coronary and peripheral arterial disease.
|d Amsterdam : Academic Press, 2021
|z 0128205369
|z 9780128205365
|w (OCoLC)1151182550
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128205365
|z Texto completo
|
